We are live on ! Find out more
MIM

Monashee Investment Management Portfolio holdings

AUM $184M
1-Year Est. Return 197.43%
This Fund
S&P 500
This Quarter Est. Return
+18.44%
1 Year Est. Return
+197.43%
3 Year Est. Return
+447.04%
5 Year Est. Return
+479.31%
10 Year Est. Return
+5,610.42%
AUM
$845M
AUM Growth
+$279M
Cap. Flow
+$203M
Cap. Flow %
23.97%
Top 10 Hldgs %
63.74%
Holding
124
New
76
Increased
6
Reduced
15
Closed
19

Top Buys

Rank Stock Value
1
BUD icon
AB InBev
BUD
+$16.9M
2
SN icon
SharkNinja
SN
+$12.6M
3
AHR icon
American Healthcare REIT
AHR
+$9.21M
4
KSPI icon
Kaspi.kz JSC
KSPI
+$8.9M
5
ODD icon
ODDITY Tech
ODD
+$8.85M

Top Sells

Rank Stock Value
1
PCG icon
PG&E
PCG
+$4.69M
2
VEA icon
Vanguard FTSE Developed Markets ETF
VEA
+$4.11M
3
GPCR icon
Structure Therapeutics
GPCR
+$4.1M
4
ARGX icon
argenx
ARGX
+$3.8M
5
LVS icon
Las Vegas Sands
LVS
+$3.69M

Sector Composition

Rank Sector Weight
1 Healthcare 15.07%
2 Industrials 5.62%
3 Consumer Staples 3.94%
4 Technology 3.82%
5 Consumer Discretionary 2.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REVG
26
DELISTED
REV Group
REVG
$5.72M 0.68%
+258,938
New +$4.84M
CGON icon
27
CG Oncology
CGON
$6.66B
$5.49M 0.65%
+125,000
New +$5.11M
KNTK icon
28
Kinetik
KNTK
$7.98B
$4.98M 0.59%
125,000
+60,100
+93% +$2.06M
KRRO icon
29
Korro Bio
KRRO
$195M
$4.98M 0.59%
55,364
-35,441
-39% -$1.93M
RDNT icon
30
RadNet
RDNT
$5.69B
$4.87M 0.58%
+100,000
New +$4.03M
DYN icon
31
Dyne Therapeutics
DYN
$4.9B
$4.83M 0.57%
+170,000
New +$3.84M
ICHR icon
32
Ichor Holdings
ICHR
$2.56B
$4.75M 0.56%
+122,960
New +$4.76M
SYM icon
33
Symbotic
SYM
$5.22B
$4.73M 0.56%
+105,161
New +$4.61M
AQST icon
34
Aquestive Therapeutics
AQST
$494M
$4.26M 0.5%
+1,000,000
New +$3.33M
GOSS icon
35
Gossamer Bio
GOSS
$87M
$4.08M 0.48%
3,459,854
– –
GPCR icon
36
Structure Therapeutics
GPCR
$3.78B
$4.06M 0.48%
94,714
-97,141
-51% -$4.1M
NAMS icon
37
NewAmsterdam Pharma
NAMS
$3.34B
$4.02M 0.48%
+170,000
New +$3.45M
MTDR icon
38
Matador Resources
MTDR
$6.09B
$4.01M 0.47%
+60,000
New +$3.57M
ARQT icon
39
Arcutis Biotherapeutics
ARQT
$3.18B
$3.77M 0.45%
+380,000
New +$2.84M
ROIV icon
40
Roivant Sciences
ROIV
$26.2B
$3.69M 0.44%
350,000
– –
SNX icon
41
TD Synnex
SNX
$20.2B
$3.68M 0.43%
+32,500
New +$3.38M
CLDX icon
42
Celldex Therapeutics
CLDX
$3.28B
$3.67M 0.43%
87,500
-12,709
-13% -$522K
NSSC icon
43
Napco Security Technologies
NSSC
$1.48B
$3.61M 0.43%
+90,000
New +$3.53M
PWP icon
44
Perella Weinberg Partners
PWP
$1.3B
$3.56M 0.42%
+252,066
New +$3.17M
AUNA
45
Auna
AUNA
$394M
$3.46M 0.41%
+325,000
New +$3.34M
EPRT icon
46
Essential Properties Realty Trust
EPRT
$6.62B
$3.33M 0.39%
+125,000
New +$3.13M
IMNM icon
47
Immunome
IMNM
$2.83B
$3.27M 0.39%
+132,500
New +$2.69M
IMVT icon
48
Immunovant
IMVT
$8.25B
$3.23M 0.38%
100,000
+30,000
+43% +$1.09M
ATMU icon
49
Atmus Filtration Technologies
ATMU
$4.18B
$3.23M 0.38%
+100,000
New +$2.39M
CHWY icon
50
Chewy
CHWY
$9.63B
$3.18M 0.38%
+200,000
New +$3.59M
1
2
3 4 5

Similar funds

SWMG
Sard Wealth Management Group Atlanta, Georgia $184M AUM 11.26% 1-Year Est. Return
IFPL
Investments & Financial Planning LLC Lexington, Kentucky $184M AUM 17.7% 1-Year Est. Return
RFG
RFP Financial Group Atlanta, Georgia $184M AUM 16.06% 1-Year Est. Return
NAM
Nutshell Asset Management Sevenoaks, United Kingdom $184M AUM 2.02% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
GCA
GSI Capital Advisors Newport Beach, California $184M AUM 5.17% 1-Year Est. Return
IVGAV
Index Venture Growth Associates V St. Helier, Jersey $184M AUM

Monashee Investment Management's Q1 2024 Portfolio in Review

As of Q1 2024, Monashee Investment Management held 124 positions worth $845M, up 49% from $567M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Monashee Investment Management deployed $203M of net new capital in Q1 2024, opening 76 new positions and adding to 6 existing holdings. Its largest new stake was AB InBev: 270,100 shares worth $16.4M.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 9.1% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Vanguard FTSE Developed Markets ETF, an estimated $4.11M trimmed.

  • Monashee Investment Management's largest Q1 2024 buy was AB InBev: 270,100 shares worth $16.4M.
  • Monashee Investment Management added most to Vaxcyte in Q1 2024, an estimated $4.33M increase.
  • Monashee Investment Management's biggest Q1 2024 reduction was Vanguard FTSE Developed Markets ETF, cutting an estimated $4.11M.
  • Monashee Investment Management fully exited PG&E in Q1 2024, selling an estimated $4.69M.
  • Monashee Investment Management's ten largest holdings make up 64% of its $845M portfolio in Q1 2024.
  • Monashee Investment Management opened 76 new positions and closed 19 in Q1 2024.
  • Monashee Investment Management's portfolio value rose 49% quarter-over-quarter to $845M.

Based on Monashee Investment Management's 13F filing for Q1 2024, filed 14 May 2024.